Japan PHarmacological Audit study of Safety and Efficacy in Realworld (Phase-R) Delirium Study

Japan PHarmacological Audit study of Safety and Efficacy in Realworld (Phase-R) Delirium Study - Phase-R Delirium Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000018589

Enrollment

1000

Registered

2015-08-10

Start date

2015-08-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignancy

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inpatients with advanced cancer aged 18 years or older who undergo antipsychotic treatments for hyper- or hypoactive delirium in palliative care units or psycho-oncology consultation settings

Exclusion criteria

Exclusion criteria: Patients with substance withdrawal delirium Patient with postoperative delirium Patients who undergo medical treatments intended to terminal sedation

Design outcomes

Primary

Measure	Time frame
Delirium Rating Scale R-98 on day 3	—

Secondary

Measure	Time frame
NuDESC item 2-4 Communication Capacity Scale item 4 Agitation Distress Scale item 2 Adverse events Drug-induced Extra-piramidal Symptom Scale(DIEPSS)	—

Countries

Japan

Contacts

Public ContactKeisuke Ariyoshi

The University of Tokyo, The Institute of Medical Science Department of Palliative Medicine

k-ariyoshi@umin.ac.jp03-3443-8111

Outcome results